Gil-Soon Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gil-Soon Choi has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Hae-Sim Park
Department of Allergy and Clinical Immunology Ajou University School of Medicine Suwon Korea
10 shared publications - Hee-Kyoo Kim
Division of Allergy, Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Republic of Korea
8 shared publications Hee-Kyoo Kim
Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
5 shared publications- Joo-Hee Kim
Department of Medicine, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang 14068, Republic of Korea
5 shared publications - Young-Min Ye
Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
5 shared publications - Gyu Young Hur
Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul 08308, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10277
Exacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
- 16 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (22) , 10277
Open AccessExacerbation of Allergic Diseases After COVID-19 Vaccination: A Multicenter Observational Study
Concerns about worsening allergic disease may contribute to vaccine hesitancy. We evaluated the frequency, severity, and factors associated with self-reported exacerbations after COVID-19 vaccination and described findings after influenza vaccination. In this multicenter observational survey, adults with physician-diagnosed allergic diseases were prospectively enrolled at 14 Korean allergy centers, while vaccination history and post-vaccination outcomes were retrospectively ascertained. Severe exacerbation was defined as requiring emergency department care or hospitalization. Among 1626 COVID-19-vaccinated patients, 281 (17.3%) reported exacerbation; 36 (12.8% of exacerbators; and 2.2% of all vaccinated patients) were severe. Female sex, chronic urticaria, and atopic dermatitis were independently associated with any exacerbation, whereas increasing age and allergic rhinitis were associated with lower odds. Bronchial asthma was independently associated with severe exacerbation (adjusted OR, 3.07; 95% CI, 1.10–8.51). No factor was associated with multiple exacerbations. Biologic therapy and allergen immunotherapy were not associated with increased risk. Exacerbations were reported in 16 of 786 influenza-vaccinated patients (2.0%) and were generally mild. Although self-reported symptom worsening after COVID-19 vaccination was relatively common, severe events were uncommon. COVID-19 vaccination was generally well tolerated, including among patients receiving biologics or allergen immunotherapy.
- Open Access
- 20 August 2026
- Published by Kosin University College of Medicine in Kosin Medical Journal
=?UTF-8?B?QXNzb2NpYXRpb24gb2YgcmVkdWN0aW9ucyBpbiBtaWNyb29yZ2FuaXNtLXNwZWNpZmljIElnRSB3aXRoIHF1YWxpdHktb2YtbGlmZSBpbXByb3ZlbWVudCBpbiBwYXRpZW50cyB3aXRoIG1vZGVyYXRlLXRvLXNldmVyZSBhdG9waWMgZGVybWF0aXRpcyB0cmVhdGVkIHdpdGggZHVwaWx1bWFi?=
Association of reductions in microorganism-specific IgE with quality-of-life improvement in patients with moderate-to-severe atopic dermatitis treated with dupilumab
- 20 August 2026
- Published by Kosin University College of Medicine in Kosin Medical Journal
Open Access=?UTF-8?B?QXNzb2NpYXRpb24gb2YgcmVkdWN0aW9ucyBpbiBtaWNyb29yZ2FuaXNtLXNwZWNpZmljIElnRSB3aXRoIHF1YWxpdHktb2YtbGlmZSBpbXByb3ZlbWVudCBpbiBwYXRpZW50cyB3aXRoIG1vZGVyYXRlLXRvLXNldmVyZSBhdG9waWMgZGVybWF0aXRpcyB0cmVhdGVkIHdpdGggZHVwaWx1bWFi?=
Association of reductions in microorganism-specific IgE with quality-of-life improvement in patients with moderate-to-severe atopic dermatitis treated with dupilumab
- Open Access
- 11 August 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Drug provocation testing for eperisone-induced immediate hypersensitivity: A case series and proposal of a risk-stratified approach
Background: Eperisone hydrochloride is a widely used muscle relaxant; however, its potential to cause immediate hypersensitivity is often overlooked because of its frequent coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs). We aimed to describe the clinical characteristics and drug provocation test (DPT) outcomes of eperisone-induced immediate hypersensitivity and to explore a pragmatic, risk-based approach based on our clinical experience. Methods: Between 2020 and 2025, we retrospectively analyzed 17 patients with suspected eperisone-induced immediate hypersensitivity. Clinical characteristics, skin prick test, intradermal test, and DPT results were evaluated. Reaction severity was graded using the 2020 World Allergy Organization (WAO) 5-grade systemic allergic reaction grading system. Results: Eperisone hypersensitivity was confirmed in 13 (76.5%) patients using DPT. All confirmed patients had negative skin prick tests, and only 1 showed a marginal intradermal reaction at the highest concentration (10 mg/mL). During DPT, 84.6% reacted at or before the second dose-escalation step. Hypersensitivity was elicited at remarkably low doses (9.37–50 mg), with severe anaphylaxis occurring at doses as low as 9.37 mg (1/8 tablet), and symptom onset occurring within 35 minutes of the last administered dose in most cases (76.9%). A total of 61.5% of confirmed patients experienced grade 3-5 reactions consistent with anaphylaxis; delate 30.8% developed grade 5 reactions, and 23.1% required repeated epinephrine administration. Although severity did not differ between formulation, sustained-release preparations were associated with delayed or prolonged reactions in some cases. Conclusion: Skin tests have limited diagnostic value for eperisone hypersensitivity. When immediate hypersensitivity occurs in the setting of concomitant NSAID use, eperisone should be actively considered as a potential culprit rather than attributing the reaction solely to NSAIDs. Because severe reactions may occur even at very low doses during DPT, it should be reserved for carefully selected patients in whom the anticipated diagnostic benefit outweighs the procedural risk, with individualized risk-reduction strategies when clinically indicated.
- 11 August 2026
- Published by Wolters Kluwer Health in Asia Pacific Allergy
Open AccessDrug provocation testing for eperisone-induced immediate hypersensitivity: A case series and proposal of a risk-stratified approach
Background: Eperisone hydrochloride is a widely used muscle relaxant; however, its potential to cause immediate hypersensitivity is often overlooked because of its frequent coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs). We aimed to describe the clinical characteristics and drug provocation test (DPT) outcomes of eperisone-induced immediate hypersensitivity and to explore a pragmatic, risk-based approach based on our clinical experience. Methods: Between 2020 and 2025, we retrospectively analyzed 17 patients with suspected eperisone-induced immediate hypersensitivity. Clinical characteristics, skin prick test, intradermal test, and DPT results were evaluated. Reaction severity was graded using the 2020 World Allergy Organization (WAO) 5-grade systemic allergic reaction grading system. Results: Eperisone hypersensitivity was confirmed in 13 (76.5%) patients using DPT. All confirmed patients had negative skin prick tests, and only 1 showed a marginal intradermal reaction at the highest concentration (10 mg/mL). During DPT, 84.6% reacted at or before the second dose-escalation step. Hypersensitivity was elicited at remarkably low doses (9.37–50 mg), with severe anaphylaxis occurring at doses as low as 9.37 mg (1/8 tablet), and symptom onset occurring within 35 minutes of the last administered dose in most cases (76.9%). A total of 61.5% of confirmed patients experienced grade 3-5 reactions consistent with anaphylaxis; delate 30.8% developed grade 5 reactions, and 23.1% required repeated epinephrine administration. Although severity did not differ between formulation, sustained-release preparations were associated with delayed or prolonged reactions in some cases. Conclusion: Skin tests have limited diagnostic value for eperisone hypersensitivity. When immediate hypersensitivity occurs in the setting of concomitant NSAID use, eperisone should be actively considered as a potential culprit rather than attributing the reaction solely to NSAIDs. Because severe reactions may occur even at very low doses during DPT, it should be reserved for carefully selected patients in whom the anticipated diagnostic benefit outweighs the procedural risk, with individualized risk-reduction strategies when clinically indicated.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (30)
Immunochemical Markers and Quality of Life in Severe Atopic Dermatitis: A Real-World Analysis
Background: Severe atopic dermatitis (AD) impacts substantially quality of life (QoL), however the major clinical and immunologic contributors to this burden remain unclear. This study aimed to compare clinical and immunochemical profiles between patients with non-severe and severe AD and to identify key factors associated with QoL impairment in those with severe disease. Methods: A retrospective analysis was conducted on 371 patients diagnosed with AD from 2020 to 2023 at Kosin University Gospel Hospital. Patients were categorized according to Eczema Area and Severity Index (EASI) scores, with severe AD defined as EASI > 21. Clinical characteristics, immunologic markers, and Dermatology Life Quality Index (DLQI) scores were assessed. Multivariate regression was used to identify factors independently associated with DLQI. Results: Among all patients, 140 (37.7%) had severe AD. This group exhibited significantly higher EASI and DLQI scores, more widespread skin involvement, and increased skin infections. Laboratory findings showed elevated total IgE, eosinophil counts, and specific IgE to Pityrosporum orbiculare. In the severe AD group, higher DLQI scores, indicating poorer QoL, were positively associated with eosinophil percentage, specific IgE to P. orbiculare, EASI score, and pruritus score, whereas total IgE and white blood cell (WBC) count showed an inverse relationship with DLQI. Conclusion: Clinical severity and immunologic activity were associated with QoL in patients with severe AD. Total IgE, specific IgE to P. orbiculare, WBC and eosinophil counts, pruritus, and EASI scores were identified as factors influencing QoL. These findings highlight the importance of heterogeneous immunologic profiles in assessing QoL in severe AD. Future large-scale cohort studies are needed to elucidate the dynamic interactions among immunologic profiles, treatment response, and QoL in severe AD.
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41 (30)
Open AccessImmunochemical Markers and Quality of Life in Severe Atopic Dermatitis: A Real-World Analysis
Background: Severe atopic dermatitis (AD) impacts substantially quality of life (QoL), however the major clinical and immunologic contributors to this burden remain unclear. This study aimed to compare clinical and immunochemical profiles between patients with non-severe and severe AD and to identify key factors associated with QoL impairment in those with severe disease. Methods: A retrospective analysis was conducted on 371 patients diagnosed with AD from 2020 to 2023 at Kosin University Gospel Hospital. Patients were categorized according to Eczema Area and Severity Index (EASI) scores, with severe AD defined as EASI > 21. Clinical characteristics, immunologic markers, and Dermatology Life Quality Index (DLQI) scores were assessed. Multivariate regression was used to identify factors independently associated with DLQI. Results: Among all patients, 140 (37.7%) had severe AD. This group exhibited significantly higher EASI and DLQI scores, more widespread skin involvement, and increased skin infections. Laboratory findings showed elevated total IgE, eosinophil counts, and specific IgE to Pityrosporum orbiculare. In the severe AD group, higher DLQI scores, indicating poorer QoL, were positively associated with eosinophil percentage, specific IgE to P. orbiculare, EASI score, and pruritus score, whereas total IgE and white blood cell (WBC) count showed an inverse relationship with DLQI. Conclusion: Clinical severity and immunologic activity were associated with QoL in patients with severe AD. Total IgE, specific IgE to P. orbiculare, WBC and eosinophil counts, pruritus, and EASI scores were identified as factors influencing QoL. These findings highlight the importance of heterogeneous immunologic profiles in assessing QoL in severe AD. Future large-scale cohort studies are needed to elucidate the dynamic interactions among immunologic profiles, treatment response, and QoL in severe AD.
- Open Access
- 25 September 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
=?UTF-8?B?RW1lcmdpbmcgcm9sZXMgb2YgdGhlIGdhc2Rlcm1pbiBmYW1pbHkgaW4gYXN0aG1h?=
Emerging roles of the gasdermin family in asthma
- 25 September 2025
- Published by Kosin University College of Medicine in Kosin Medical Journal
Open Access=?UTF-8?B?RW1lcmdpbmcgcm9sZXMgb2YgdGhlIGdhc2Rlcm1pbiBmYW1pbHkgaW4gYXN0aG1h?=
Emerging roles of the gasdermin family in asthma
- Open Access
- 30 August 2025
- Published by Elsevier in Safety and Health at Work
- Vol. 16 (4) , 454-461
Trends in Occupational Skin Disease among Korean Workers (2006–2017): Insights Into Declining Prevalence and Demographic Shifts
- 30 August 2025
- Published by Elsevier in Safety and Health at Work
- Vol. 16 (4) , 454-461
Open AccessTrends in Occupational Skin Disease among Korean Workers (2006–2017): Insights Into Declining Prevalence and Demographic Shifts
- Open Access
- 25 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320427
PGAP3 is expressed at increased levels in asthmatic ASM and is associated with increased ASM proliferation, contractility and expression of GATA3 and ALOX5
Post-GPI Attachment to Proteins phospholipase 3 (PGAP3) is a glycosylphosphatidylinositol (GPI) anchor-remodeling gene found on chromosome 17q12-21, which is a locus highly linked to asthma. Genetic association studies have linked PGAP3 SNPs to increased PGAP3 expression as well as asthma exacerbations, severity, and susceptibility. This study compared the levels of PGAP3 mRNA expression quantitated by RT-qPCR in human bronchial airway smooth muscle cells derived from postmortem lungs of asthmatics (ASM-A) to that derived from control non-asthmatics (ASM-NA). ASM-A expressed significantly higher levels of PGAP3 mRNA compared to ASM-NA. As ASM-A expressed higher levels of PGAP3 mRNA we performed functional studies of ASM-NA transfected with PGAP3 to determine if increased PGAP3 expression in ASM influenced ASM function including proliferation and contractility. Functional studies of ASM transfected with PGAP3 demonstrated that increased PGAP3 expression in ASM resulted in increased ASM proliferation and contractility. RNA-seq studies of ASM transfected with PGAP3 demonstrated significantly increased levels of genes linked to asthma including GATA3 and ALOX5. Fifteen genes upregulated by PGAP3 in ASM-NA were detected in asthmatic ASM data sets, underscoring the ability of PGAP3 to induce genes of importance to asthma in ASM. In summary, this study made the novel observation that ASM derived from the lungs of asthmatics express higher levels of PGAP3 compared to non-asthmatics. In addition, when ASM from non-asthmatics are transfected with PGAP3, the increased levels of PGAP3 increase ASM proliferation and contractility, and increase levels of genes previously linked to asthma including GATA3 and ALOX5. Overall, these studies suggest that increased PGAP3 expression in ASM plays a functional role in contributing to the pathogenesis of asthma.
- 25 March 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (3) , e0320427
Open AccessPGAP3 is expressed at increased levels in asthmatic ASM and is associated with increased ASM proliferation, contractility and expression of GATA3 and ALOX5
Post-GPI Attachment to Proteins phospholipase 3 (PGAP3) is a glycosylphosphatidylinositol (GPI) anchor-remodeling gene found on chromosome 17q12-21, which is a locus highly linked to asthma. Genetic association studies have linked PGAP3 SNPs to increased PGAP3 expression as well as asthma exacerbations, severity, and susceptibility. This study compared the levels of PGAP3 mRNA expression quantitated by RT-qPCR in human bronchial airway smooth muscle cells derived from postmortem lungs of asthmatics (ASM-A) to that derived from control non-asthmatics (ASM-NA). ASM-A expressed significantly higher levels of PGAP3 mRNA compared to ASM-NA. As ASM-A expressed higher levels of PGAP3 mRNA we performed functional studies of ASM-NA transfected with PGAP3 to determine if increased PGAP3 expression in ASM influenced ASM function including proliferation and contractility. Functional studies of ASM transfected with PGAP3 demonstrated that increased PGAP3 expression in ASM resulted in increased ASM proliferation and contractility. RNA-seq studies of ASM transfected with PGAP3 demonstrated significantly increased levels of genes linked to asthma including GATA3 and ALOX5. Fifteen genes upregulated by PGAP3 in ASM-NA were detected in asthmatic ASM data sets, underscoring the ability of PGAP3 to induce genes of importance to asthma in ASM. In summary, this study made the novel observation that ASM derived from the lungs of asthmatics express higher levels of PGAP3 compared to non-asthmatics. In addition, when ASM from non-asthmatics are transfected with PGAP3, the increased levels of PGAP3 increase ASM proliferation and contractility, and increase levels of genes previously linked to asthma including GATA3 and ALOX5. Overall, these studies suggest that increased PGAP3 expression in ASM plays a functional role in contributing to the pathogenesis of asthma.
- Open Access
- 4 April 2024
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 14 (3) , 139-142
Successful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review
Atezolizumab, a humanized antiprogrammed death ligand 1 monoclonal immunoglobulin G1 antibody, is a targeted therapeutic drug known as an immune checkpoint inhibitor. It is currently used to treat various types of cancer, including unresectable hepatocellular carcinoma (HCC), nonsmall cell lung cancer, urothelial cancer, and breast cancer, and is becoming a therapeutic option in the forefront of oncology treatment. However, it may sometimes lead to undesirable adverse reactions owing to the activation of immune responses in various organs. Cutaneous adverse reactions to atezolizumab are well known; however, cases of anaphylaxis are very rare. In this report, we present the first case of HCC who experienced near-fatal anaphylaxis to atezolizumab in South Korea.
- 4 April 2024
- Published by Wolters Kluwer Health in Asia Pacific Allergy
- Vol. 14 (3) , 139-142
Open AccessSuccessful desensitization to atezolizumab-induced near-fatal anaphylaxis in patients with hepatocellular carcinoma: A case report and literature review
Atezolizumab, a humanized antiprogrammed death ligand 1 monoclonal immunoglobulin G1 antibody, is a targeted therapeutic drug known as an immune checkpoint inhibitor. It is currently used to treat various types of cancer, including unresectable hepatocellular carcinoma (HCC), nonsmall cell lung cancer, urothelial cancer, and breast cancer, and is becoming a therapeutic option in the forefront of oncology treatment. However, it may sometimes lead to undesirable adverse reactions owing to the activation of immune responses in various organs. Cutaneous adverse reactions to atezolizumab are well known; however, cases of anaphylaxis are very rare. In this report, we present the first case of HCC who experienced near-fatal anaphylaxis to atezolizumab in South Korea.
- Open Access
- 31 March 2024
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 39 (1) , 51-59
Clinical efficacy and safety of autologous serum intramuscular injection in patients with mild-to-moderate atopic dermatitis: a prospective, open-label, uncontrolled study
Background: Autologous blood therapy (ABT) has been used to treat atopic dermatitis (AD) for over a century, even though evidence supporting its efficacy is lacking. We aimed to investigate the effectiveness and safety of autologous serum intramuscular injection (ASIM), which is a modified form of ABT, in treating mild-to-moderate AD. Methods: This study was a 12-week, open-label, prospective, uncontrolled trial. Following a 4-week run-in period, 22 out of 25 screened patients received ASIM once a week for 4 weeks in conjunction with standard treatment. The primary outcome measure was the Eczema Area and Severity Index (EASI), while the secondary outcomes included the Scoring Atopic Dermatitis (SCORAD) score, Dermatologic Life Quality Index (DLQI), and patient ratings of pruritus, sleep difficulty, disease status, and treatment effectiveness. Safety parameters were also assessed. Results: EASI scores showed a non-statistically significant trend toward improvement during ASIM intervention. Patients with at least a 50% improvement in the EASI score at 4 weeks were older and had lower peripheral eosinophil counts (p<0.05). Secondary endpoints, including the SCORAD score, pruritus, sleep difficulty, and DLQI, demonstrated statistically significant improvements at week 4 compared to baseline (p<0.05). No significant adverse reactions were observed. Conclusions: This pioneering study suggests that repeated ASIM may improve the clinical symptoms of mild-to-moderate AD, particularly in terms of pruritus and overall quality of life. However, further research with a larger sample size is required to establish the clinical significance of these findings.
- 31 March 2024
- Published by Kosin University College of Medicine in Kosin Medical Journal
- Vol. 39 (1) , 51-59
Open AccessClinical efficacy and safety of autologous serum intramuscular injection in patients with mild-to-moderate atopic dermatitis: a prospective, open-label, uncontrolled study
Background: Autologous blood therapy (ABT) has been used to treat atopic dermatitis (AD) for over a century, even though evidence supporting its efficacy is lacking. We aimed to investigate the effectiveness and safety of autologous serum intramuscular injection (ASIM), which is a modified form of ABT, in treating mild-to-moderate AD. Methods: This study was a 12-week, open-label, prospective, uncontrolled trial. Following a 4-week run-in period, 22 out of 25 screened patients received ASIM once a week for 4 weeks in conjunction with standard treatment. The primary outcome measure was the Eczema Area and Severity Index (EASI), while the secondary outcomes included the Scoring Atopic Dermatitis (SCORAD) score, Dermatologic Life Quality Index (DLQI), and patient ratings of pruritus, sleep difficulty, disease status, and treatment effectiveness. Safety parameters were also assessed. Results: EASI scores showed a non-statistically significant trend toward improvement during ASIM intervention. Patients with at least a 50% improvement in the EASI score at 4 weeks were older and had lower peripheral eosinophil counts (p<0.05). Secondary endpoints, including the SCORAD score, pruritus, sleep difficulty, and DLQI, demonstrated statistically significant improvements at week 4 compared to baseline (p<0.05). No significant adverse reactions were observed. Conclusions: This pioneering study suggests that repeated ASIM may improve the clinical symptoms of mild-to-moderate AD, particularly in terms of pruritus and overall quality of life. However, further research with a larger sample size is required to establish the clinical significance of these findings.
- Open Access
- 1 January 2024
- Published by XMLink in Allergy Asthma & Respiratory Disease
- Vol. 12 (2) , 85-92
Analysis of patch test results in patients with suspected contact dermatitis in the Busan area
김광석, et al. Allergy Asthma Respir Dis. 2024 Apr;12(2):85-92. https://doi.org/10.4168/aard.2024.12.2.85
- 1 January 2024
- Published by XMLink in Allergy Asthma & Respiratory Disease
- Vol. 12 (2) , 85-92
Open AccessAnalysis of patch test results in patients with suspected contact dermatitis in the Busan area
김광석, et al. Allergy Asthma Respir Dis. 2024 Apr;12(2):85-92. https://doi.org/10.4168/aard.2024.12.2.85